Risankizumab Long-term Remission Study
Public ClinicalTrials.gov record NCT04630652. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Immune Modification of Psoriasis by Selective IL-23 Blockade Using Risankizumab
Study identification
- NCT ID
- NCT04630652
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Jaehwan Kim
- Other
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Interventions
- Punch biopsies of the skin at baseline visit Procedure
- Punch biopsies of the skin at week 28 visit Procedure
- Risankizumab-Rzaa Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 6, 2021
- Primary completion
- Feb 27, 2026
- Completion
- Jul 27, 2027
- Last update posted
- Nov 2, 2025
2021 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VA Northern California Health Care System | Sacramento | California | 95655 | — |
| University of California Davis Medical Center | Sacramento | California | 95817 | — |
| The Rockefeller Univesity | New York | New York | 10065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04630652, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04630652 live on ClinicalTrials.gov.